Inherited Variants in BLM and the Risk and Clinical Characteristics of Breast Cancer

Area of Science:

• Genetics
• Oncology
• Molecular Biology

Background:

• Bloom syndrome, a rare recessive disorder, is linked to increased cancer susceptibility due to homozygous BLM gene mutations.
• The role of heterozygous BLM mutations in cancer predisposition, particularly breast cancer, remains largely unexplored.

Purpose of the Study:

• To investigate the potential association between heterozygous BLM mutations and breast cancer risk.
• To determine if a specific BLM founder mutation predisposes individuals to breast cancer.

Main Methods:

• Sequencing of the BLM gene in 617 breast cancer patients with a strong family history.
• Genotyping of a identified founder mutation (c.1642C>T, p.Gln548Ter) in 14,804 unselected breast cancer cases and 4,698 cancer-free controls.
• Analysis of clinical characteristics and allelic status in tumors from mutation carriers.

Main Results:

• A BLM founder mutation was detected in 0.49% of familial breast cancer patients.
• The mutation prevalence was similar in unselected breast cancer cases (0.55%) and controls (0.55%), with an odds ratio of 1.0.
• No significant differences in breast cancer characteristics or increased cancer incidence in relatives were observed between mutation carriers and non-carriers.

Conclusions:

• The BLM founder mutation p.Gln548Ter does not appear to confer a predisposition to breast cancer in heterozygous carriers.
• The findings challenge the classification of BLM as an autosomal dominant breast cancer susceptibility gene.
• Further research is warranted to fully elucidate the role of BLM in cancer etiology.